Locally delivered polyclonal antibodies potentiate intravenous antibiotic efficacy against gram-negative infections

Pharmaceutical Research

Volumn 19, Issue 12, 2002, Pages 1801-1807

  Barekzi, Nazir A ^a   Felts, Adrian G ^a   Poelstra, Kornelis A ^a   Slunt, Jeffrey B ^a   Grainger, David W ^b  

^a Medical Sciences Research Institute   (United States)

^b Veterinary Dentistry and Oral Surgery   (United States)

Author keywords

Antibiotic; Antibody delivery; Immunoglobulin; Infection; Synergy

Indexed keywords

ANTIBIOTIC AGENT; CEFTAZIDIME; IMMUNOGLOBULIN G; METHOXYFLURANE; POLYCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMICROBIAL ACTIVITY; ARTICLE; BURN INFECTION; CYTOKINE PRODUCTION; DISEASE MODEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG INFUSION; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; MOUSE; NONHUMAN; OUTBRED STRAIN; PERITONITIS; PRIORITY JOURNAL; SEPSIS; SURVIVAL;

ANIMALS; ANTI-BACTERIAL AGENTS; CEFTAZIDIME; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MICE; PERITONITIS; SURVIVAL RATE; WOUND INFECTION;

EID: 0036917522     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1021481122011     Document Type: Article

References (32)

1. H. C. Neu. The crisis in antibiotic resistance. Science 257:1064-1073 (1992).
2. H. S. Gold and R. C. Moellering. Antimicrobial-drug resistance. N. Engl. J. Med. 335:1445-1453 (1996).
3. S. Monroe and R. Polk. Antimicrobial use and bacterial resistance. Curr. Opin. Microbiol. 3:496-501 (2000).
4. W. Wong and D. L. Pompliano. In B. Rosen and S. Mobashery (eds.), Resolving the Antibiotic Paradox: Progress in Drug Design and Resistance, Plenum, New York, 1999, pp. 1-21.
5. D. T. Moir, K. J. Shaw, R. S. Hare, and G. F. Vovis. Genomics and antimicrobial drug discovery. Antimicrob. Agents Chemother. 43:439-446 (1999).
6. A. Persidis. Antibacterial and antifungal drug discovery. Nature Biotechnol. 17:1141-1142 (1999).
7. J. A. DeVito, J. A. Mills, V. G. Liu, A. Agarwal, C. F. Sizemore, Z. Yao, D. M. Stoughton, M. G. Cappiello, M. D. F. S. Barbosa, L. A. Foster, and D. L. Pompliano. An array of target-specific screening strains for antibacterial discovery. Nature Biotechnol. 20:478-483 (2002).
8. A. Casadevall. Antibody-based therapies for emerging infectious diseases. Emerg. Infect. Dis. 2:200-208 (1996).
9. R. H. Buckley and R. I. Schiff. The use of intravenous immune globulin in immunodeficiency diseases. N. Engl. J. Med. 325:110-117 (1991).
10. C. G. Gemmell. Does the appearance of drug resistance during therapy alter bacterial susceptibility to opsonophagocytosis? Drugs Exp. Clin. Res. 22:51-55 (1996).
11. A. Cometta, J. D. Baumgartner, and M. P. Glauser. Polyclonal intravenous immune globulin for prevention and treatment of infections in critically ill patients. Clin. Exp. Immunol. 97:69-72 (1994).
12. G. R. Siber. Immune globulin to prevent nosocomial infections. N. Engl. J. Med. 327:269-271 (1992).
13. K. N. Haque, C. Remo, and H. Bahakim. Comparison of two types of intravenous immunoglobulins in the treatment of neonatal sepsis. Clin. Exp. Immunol. 101:328-333 (1995).
14. F. Cafiero, M. Gipponi, U. Bonalumi, A. Piccardo, C. Sguotti, and G. Corbetta. Prophylaxis of infection with intravenous immunoglobulins plus antibiotic for patients at risk for sepsis undergoing surgery for colorectal cancer: Results of a randomized, multicenter clinical trial. Surgery 112:24-31 (1992).
15. K. S. Lamp, M. J. Rybak, B. J. McGrath, and K. K. Summers. Influence of antibiotic and E5 monoclonal immunoglobulin M interactions on endotoxin release from Escherichia coli and Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 40:247-252 (1996).
16. H. S. El-Zaim, A. K. Chopra, J. W. Peterson, M. L. Vasil, and J. P. Heggers. Protection against exotoxin A (ETA) and Pseudomonas aeruginosa infection in mice with ETA-specific antipeptide antibodies. Infect. Immun. 66:5551-5554 (1998).
17. J. E. Van Wye, M. S. Collins, M. Baylor, J. E. Pennington, Y. P. Hsu, V. Sampanvejsopa, and R. B. Moss. Pseudomonas hyperimmune globulin passive immunotherapy for pulmonary exacerbations in cystic fibrosis. Pediatr. Pulmonol. 9:7-18 (1990).
18. R. Malley, J. DeVincenzo, O. Ramilo, P. H. Dennehy, H. C. Meissner, W. C. Gruber, P. J. Sanchez, H. Jafri, J. Balsley, D. Carlin, S. Buckingham, L. Vernacchio, and D. M. Ambrosino. Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J. Infect. Dis. 178:1555-1561 (1998).
19. L. B. Rice, E. C. Eckstein, J. DeVente, and D. M. Shlaes. Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center. Clin. Infect. Dis. 23:118-124 (1996).
20. J. Wiener, J. P. Quinn, P. A. Bradford, R. V. Goering, C. Nathan, K. Bush, and R. A. Weinstein. Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. JAMA 281:517-523 (1999).
21. S. C. Lee, C. P. Fung, P. Y. Liu, T. C. Wang, L. C. See, N. Lee, S. C. Chen, and W. B. Shieh. Nosocomial infections with ceftazidime-resistant Pseudomonas aeruginosa: Risk factors and outcome. Infect. Control Hosp. Epidemiol. 20:205-207 (1999).
22. A. Felts, D. W. Grainger, and J. B. Slunt. Locally delivered antibodies combined with systemic antibiotics confer synergistic protection against antibiotic resistant burn wound infections. J. Trauma 49:873-878 (2000).
23. N. A. Barekzi, K. A. Poelstra, A. G. Felts, I. A. Rojas, J. B. Slunt, and D. W. Grainger. Efficacy of locally delivered polyclonal immunoglobulin against Pseudomonas aeruginosa peritonitis in a murine model. Antimicrob. Agents Chemother. 43:1609-1615 (1999).
24. A. G. Felts, G. Giridhar, D. W. Grainger, and J. B. Slunt. Efficacy of locally delivered polyclonal immunoglobulin agains Pseudomonas aeruginosa infection in a murine burn wound model. Burns 25:415-423 (1999).
25. National Research Council. In N.Grossblatt (ed.), Guide for the Care and Use of Laboratory Animals, National Academy Press, Washington DC, 1996.
26. P. S. Hiemstra, J. Brands-Tajouiti, and R. van Furth. Comparison of antibody activity against various microorganisms in intravenous immunoglobulin preparations determined by ELISA and opsonic assay. J. Lab. Clin. Med. 123:241-246 (1994).
27. D. C. Straus. Production of an extracellular toxic complex by various strains of Klebsiella pneumoniae. Infect. Immun. 55:44-48 (1987).
28. M. S. Collins, R. F. Hector, R. E. Roby, A. A. Edwards, D. K. Ladehoff, and J. H. Dorsey. Prevention of gram-negative and gram-positive infections in rodents with three intravenous immunoglobulins and therapy of experimental polymicrobial burn wound sepsis with Pseudomonas immunoglobulin and ciprofloxacin. Infection 15:S51-S59 (1987).
29. K. A. Poelstra, N. A. Barekzi, A. M. Rediske, A. G. Felts, J. B. Slunt, and D. W. Grainger. Prophylactic treatment of gram-positive and gram-negative abdominal implant infections using locally delivered polyclonal antibodies. J. Biomed. Mater. Res. 60:206-215 (2002).
30. A. Dalhoff. Synergy between acylureidopenicillins and immunoglobulin G in experimental animals. Am. J. Med. 76:91-100 (1984).
31. D. R. Absolom, C. J. van Oss, W. Zingg, and A. W. Neumann. Phagocytosis as a surface phenomenon: Opsonization by aspecific adsorption of Antibody as a function of bacterial hydrophobicity. J. Reticuloendothel. Soc. 31:59-70 (1982).
32. O. Mimoz, A. Jacolot, C. Padoin, J. Caillon, K. Louchahi, M. Tod, K. Samii, and O. Petitjean. Cefepime and amikacin synergy against a cefotaxime-susceptible strain of Enterobacter cloacae in vitro and in vivo. J. Antimicrob. Chemother. 39:363-369 (1997).